[Cutaneus vasoconstrictive effect of mineralocorticoids].
D000287:Administration, Topical; D000450:Aldosterone / Q000008:administration & dosage / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D003900:Desoxycorticosterone / Q000008:administration & dosage / Q000494:pharmacology; D005443:Flumethasone / Q000008:administration & dosage / Q000494:pharmacology; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D006854:Hydrocortisone; D008901:Mineralocorticoids / Q000494:pharmacology*; D009779:Occlusive Dressings; D012867:Skin / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D008901:Mineralocorticoids; D014662:Vasoconstrictor Agents; D005446:Fluocinolone Acetonide; D003900:Desoxycorticosterone; D000450:Aldosterone; D005443:Flumethasone; D006854:Hydrocortisone
Hautvasoconstrictionseffekt von Mineralocorticoiden